Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Date:9/18/2008

BOSTON, Sept. 18 /PRNewswire/ -- Scimitar Equity, LLC issues a Q4/08 review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "Defining Outcome Scenarios, Probabilities Appear Focused to the Upside and Future Appreciation." This review is available at our website: http://www.scimitarequity.com

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc. is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTII (NASDAQ) and its or their securities. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity, LLC

Henry W. McCusker

Director of Research

phone: (617) 559.1080

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
2. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies CEO to Retire on December 31, 2008
4. Neurobiological Technologies Reports Third Quarter Financial Results
5. Neurobiological Technologies Sets Date for Third Quarter Financial Results
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
8. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
9. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of ... the world’s leading maker of unmanned aircraft systems (UAS), are launching a joint ... use drones effectively, and support educational outreach efforts. , AMA and DJI will ...
(Date:2/16/2017)... Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power ... triple negative breast cancer (TNBC), announced today their completion of ... The YEi Start in France ... their business in France and Europe.  ... complete an intensive one week immersion in France ...
(Date:2/16/2017)... Research and Markets has announced ... report to their offering. ... The study ... delivery plasmids, chassis organisms, synthetic cells, production systems), enabling ... bioinformatics and specialty media) and enabled technologies (biofuels, chemicals, ...
(Date:2/16/2017)... , Feb. 16, 2017 UCHealth ( ... utilize LungDirect for pulmonary nodule patient management. In addition ... or a spot on the lung, UCHealth looks to ... manual data entry. Stephanie Brown, RN ... my nodule patients with an Excel spreadsheet, which was ...
Breaking Biology Technology:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):